87 related articles for article (PubMed ID: 16246487)
1. Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer.
Lyakhovich A; Surralles J
Cancer Lett; 2006 Jan; 232(1):99-106. PubMed ID: 16246487
[TBL] [Abstract][Full Text] [Related]
2. Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
Stecklein SR; Jensen RA
Transl Res; 2012 Sep; 160(3):178-97. PubMed ID: 22683426
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the FA/BRCA pathway in bladder cancer.
Neveling K; Kalb R; Florl AR; Herterich S; Friedl R; Hoehn H; Hader C; Hartmann FH; Nanda I; Steinlein C; Schmid M; Tonnies H; Hurst CD; Knowles MA; Hanenberg H; Schulz WA; Schindler D
Cytogenet Genome Res; 2007; 118(2-4):166-76. PubMed ID: 18000367
[TBL] [Abstract][Full Text] [Related]
4. The Fanconi Anemia/BRCA pathway: new faces in the crowd.
Kennedy RD; D'Andrea AD
Genes Dev; 2005 Dec; 19(24):2925-40. PubMed ID: 16357213
[TBL] [Abstract][Full Text] [Related]
5. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract][Full Text] [Related]
6. The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen F
Leuk Lymphoma; 2015 Mar; 56(3):755-62. PubMed ID: 24996439
[TBL] [Abstract][Full Text] [Related]
7. Impaired removal of DNA interstrand cross-link in Nijmegen breakage syndrome and Fanconi anemia, but not in BRCA-defective group.
Tsuchida K; Komatsu K
Cancer Sci; 2008 Nov; 99(11):2238-43. PubMed ID: 18771529
[TBL] [Abstract][Full Text] [Related]
8. Activation of the Fanconi anemia/BRCA pathway and recombination repair in the cellular response to solar ultraviolet light.
Dunn J; Potter M; Rees A; Rünger TM
Cancer Res; 2006 Dec; 66(23):11140-7. PubMed ID: 17145857
[TBL] [Abstract][Full Text] [Related]
9. No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia.
Meyer S; White DJ; Will AM; Eden T; Sim A; Brown R; Strathdee G
Br J Haematol; 2006 Jul; 134(1):61-3. PubMed ID: 16803569
[TBL] [Abstract][Full Text] [Related]
10. The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair.
Mirchandani KD; D'Andrea AD
Exp Cell Res; 2006 Aug; 312(14):2647-53. PubMed ID: 16859679
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment.
Martinez A; Hinz JM; Gómez L; Molina B; Acuña H; Jones IM; Frias S; Coleman MA
Mutat Res; 2008 Oct; 656(1-2):1-7. PubMed ID: 18647660
[TBL] [Abstract][Full Text] [Related]
12. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.
Gallmeier E; Calhoun ES; Rago C; Brody JR; Cunningham SC; Hucl T; Gorospe M; Kohli M; Lengauer C; Kern SE
Gastroenterology; 2006 Jun; 130(7):2145-54. PubMed ID: 16762635
[TBL] [Abstract][Full Text] [Related]
13. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2.
Godthelp BC; van Buul PP; Jaspers NG; Elghalbzouri-Maghrani E; van Duijn-Goedhart A; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Oct; 601(1-2):191-201. PubMed ID: 16920162
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
[TBL] [Abstract][Full Text] [Related]
15. Fancf-deficient mice are prone to develop ovarian tumours.
Bakker ST; van de Vrugt HJ; Visser JA; Delzenne-Goette E; van der Wal A; Berns MA; van de Ven M; Oostra AB; de Vries S; Kramer P; Arwert F; van der Valk M; de Winter JP; te Riele H
J Pathol; 2012 Jan; 226(1):28-39. PubMed ID: 21915857
[TBL] [Abstract][Full Text] [Related]
16. Fanconi anaemia genes and susceptibility to cancer.
Mathew CG
Oncogene; 2006 Sep; 25(43):5875-84. PubMed ID: 16998502
[TBL] [Abstract][Full Text] [Related]
17. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models.
Gallmeier E; Kern SE
Clin Cancer Res; 2007 Jan; 13(1):4-10. PubMed ID: 17200332
[TBL] [Abstract][Full Text] [Related]
18. Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway.
Soulier J; Leblanc T; Larghero J; Dastot H; Shimamura A; Guardiola P; Esperou H; Ferry C; Jubert C; Feugeas JP; Henri A; Toubert A; Socié G; Baruchel A; Sigaux F; D'Andrea AD; Gluckman E
Blood; 2005 Feb; 105(3):1329-36. PubMed ID: 15383454
[TBL] [Abstract][Full Text] [Related]
19. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers.
D'Andrea AD
Cell Cycle; 2003; 2(4):290-2. PubMed ID: 12851475
[TBL] [Abstract][Full Text] [Related]
20. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS
Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
